PofoliaShared via Pofolia

Experimental & Molecular Medicine· 2013Q1

Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine

Matthew B. Murphy, Kathryn Moncivais, Arnold I. Caplan

Short summary

Mesenchymal stem cells (MSCs) offer a novel therapeutic approach by responding to local microenvironmental cues to secrete bioactive factors, promoting tissue regeneration and immune modulation, with autologous therapies showing promise due to safety and regulatory advantages over allogeneic treatments.

AI-generated from the title and abstract; the full text is not read.

Key points

  • MSCs are defined by their ability to differentiate and, more importantly, by their trophic, paracrine, and immunomodulatory functions.
  • MSCs are site-regulated, secreting factors at variable concentrations based on local microenvironmental cues.
  • The anti-inflammatory and immunomodulatory capacity of MSCs is crucial for restoring normal healing and tissue regeneration.
  • Autologous MSC therapies are emerging as an attractive alternative to allogeneic treatments due to safety and regulatory concerns.

AI-generated from the title and abstract; the full text is not read.

Abstract

Mesenchymal stem cells (MSCs) are partially defined by their ability to differentiate into tissues including bone, cartilage and adipose in vitro, but it is their trophic, paracrine and immunomodulatory functions that may have the greatest therapeutic impact in vivo. Unlike pharmaceutical treatments that deliver a single agent at a specific dose, MSCs are site regulated and secrete bioactive factors and signals at variable concentrations in response to local microenvironmental cues. Significant progress has been made in understanding the biochemical and metabolic mechanisms and feedback associated with MSC response. The anti-inflammatory and immunomodulatory capacity of MSC may be paramount in the restoration of localized or systemic conditions for normal healing and tissue regeneration. Allogeneic MSC treatments, categorized as a drug by regulatory agencies, have been widely pursued, but new studies demonstrate the efficacy of autologous MSC therapies, even for individuals affected by a disease state. Safety and regulatory concerns surrounding allogeneic cell preparations make autologous and minimally manipulated cell therapies an attractive option for many regenerative, anti-inflammatory and autoimmune applications.

The authors' abstract, as published at the source. Experimental & Molecular Medicine, 2013 · DOI ↗

TakeawaysPremium
Ask the paperFree account

Continue with a free account

Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.

Continue free on the web

Sign in with Google or Apple; no card needed. You come back to this paper.

On your phone:

Field: Genetics (Medicine)

GeneticsMedicine